• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿尔茨海默病的诊断与治疗

Diagnosis and treatment of Alzheimer's disease.

作者信息

Grossberg George T

机构信息

Department of Psychiatry, St. Louis University School of Medicine, St. Louis, MO 63104, USA.

出版信息

J Clin Psychiatry. 2003;64 Suppl 9:3-6.

PMID:12934967
Abstract

The defining characteristic of Alzheimer's disease is cognitive impairment, but commonly this impairment is accompanied by mood and behavioral symptoms such as depression, anxiety, irritability, inappropriate behavior, sleep disturbance, psychosis, and agitation. The symptoms of Alzheimer's disease are not normative to the aging process. Diagnosis of Alzheimer's disease in the majority of cases can be made with confidence through office-based clinical assessment and informant interview. Alzheimer's disease is the most common of the dementing disorders and is exponentially increasing in incidence, projected to affect 8.64 million people in the United States by the year 2047. At present, no treatment can prevent or cure Alzheimer's disease, and the fact that Alzheimer's affects a geriatric population makes treatment all the more challenging. Therapies that could delay onset of symptoms even briefly would have a major impact on public health. As the prevalence of Alzheimer's disease increases, researchers are examining the efficacy of treatment options beyond the realm of the established cholinesterase inhibitors.

摘要

阿尔茨海默病的决定性特征是认知障碍,但通常这种障碍会伴有情绪和行为症状,如抑郁、焦虑、易怒、不当行为、睡眠障碍、精神病和激越。阿尔茨海默病的症状并非衰老过程的正常表现。在大多数情况下,通过门诊临床评估和信息提供者访谈,可以可靠地诊断出阿尔茨海默病。阿尔茨海默病是最常见的痴呆症,发病率呈指数级增长,预计到2047年美国将有864万人受其影响。目前,没有治疗方法能够预防或治愈阿尔茨海默病,而且阿尔茨海默病影响老年人群这一事实使得治疗更具挑战性。即使能短暂延迟症状发作的疗法也会对公共卫生产生重大影响。随着阿尔茨海默病患病率的上升,研究人员正在研究既定胆碱酯酶抑制剂领域之外的治疗方案的疗效。

相似文献

1
Diagnosis and treatment of Alzheimer's disease.阿尔茨海默病的诊断与治疗
J Clin Psychiatry. 2003;64 Suppl 9:3-6.
2
Early diagnosis and management of Alzheimer's disease.阿尔茨海默病的早期诊断与管理
J Clin Psychiatry. 1998;59 Suppl 9:15-21.
3
Current treatments for Alzheimer's disease: cholinesterase inhibitors.阿尔茨海默病的现有治疗方法:胆碱酯酶抑制剂。
J Clin Psychiatry. 2003;64 Suppl 9:11-7.
4
Navigating patients and caregivers through the course of Alzheimer's disease.引导患者及其护理人员度过阿尔茨海默病病程。
J Clin Psychiatry. 2006;67 Suppl 3:8-14; quiz 23.
5
Assessment of treatment-associated changes in behavior and cholinergic therapy of neuropsychiatric symptoms in Alzheimer's disease.阿尔茨海默病中与治疗相关的行为变化评估及神经精神症状的胆碱能治疗
J Clin Psychiatry. 1998;59 Suppl 13:23-30.
6
Practical treatment strategies for patients with Alzheimer's disease.阿尔茨海默病患者的实用治疗策略。
J Fam Pract. 2007 Dec;56(12 Suppl New):S17-23.
7
The need for a consensus in the use of assessment tools for Alzheimer's disease: the Feasibility Study (assessment tools for dementia in Alzheimer Centres across Europe), a European Alzheimer's Disease Consortium's (EADC) survey.阿尔茨海默病评估工具使用达成共识的必要性:可行性研究(欧洲各地阿尔茨海默病中心的痴呆评估工具),欧洲阿尔茨海默病协会(EADC)的一项调查。
Int J Geriatr Psychiatry. 2005 Aug;20(8):744-8. doi: 10.1002/gps.1355.
8
Recommendations for best practices in the treatment of Alzheimer's disease in managed care.管理式医疗中阿尔茨海默病治疗的最佳实践建议。
Am J Geriatr Pharmacother. 2006;4 Suppl A:S9-S24; quiz S25-S28. doi: 10.1016/j.amjopharm.2006.10.001.
9
Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.阿尔茨海默病行为症状的治疗策略:聚焦早期药物干预
Pharmacotherapy. 2007 Mar;27(3):399-411. doi: 10.1592/phco.27.3.399.
10
2008 Alzheimer's disease facts and figures.2008年阿尔茨海默病事实与数据。
Alzheimers Dement. 2008 Mar;4(2):110-33. doi: 10.1016/j.jalz.2008.02.005.

引用本文的文献

1
Safety, tolerability, pharmacokinetic and pharmacodynamic effects of the muscarinic M positive allosteric modulator VU0467319 for Alzheimer's disease: a single ascending-dose study in healthy participants.毒蕈碱M型正变构调节剂VU0467319用于阿尔茨海默病的安全性、耐受性、药代动力学和药效学效应:一项在健康受试者中的单剂量递增研究
Alzheimers Res Ther. 2025 Jul 1;17(1):144. doi: 10.1186/s13195-025-01798-4.
2
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of the Muscarinic M 1 Positive Allosteric Modulator VU0467319 for Alzheimer's disease: A Single Ascending-Dose Study in Healthy Participants.毒蕈碱M1型正变构调节剂VU0467319用于阿尔茨海默病的安全性、耐受性、药代动力学和药效学效应:一项在健康受试者中的单剂量递增研究
Res Sq. 2025 Apr 4:rs.3.rs-6271510. doi: 10.21203/rs.3.rs-6271510/v1.
3
Sigma receptors and neurological disorders.Sigma 受体与神经疾病。
Pharmacol Rep. 2021 Dec;73(6):1582-1594. doi: 10.1007/s43440-021-00310-7. Epub 2021 Aug 5.
4
The role of caregiver burden in the familial functioning, social support, and quality of family life of family caregivers of elders with dementia.照顾者负担在老年痴呆症患者家庭照顾者的家庭功能、社会支持及家庭生活质量中的作用。
J Rural Med. 2019 Nov;14(2):156-164. doi: 10.2185/jrm.2999. Epub 2019 Nov 20.
5
Synthesis of Novel Baicalein Amino Acid Derivatives and Biological Evaluation as Neuroprotective Agents.新型黄芩素氨基酸衍生物的合成及作为神经保护剂的生物学评价。
Molecules. 2019 Oct 9;24(20):3647. doi: 10.3390/molecules24203647.
6
Therapeutic Potential of Oridonin and Its Analogs: From Anticancer and Antiinflammation to Neuroprotection.冬凌草甲素及其类似物的治疗潜力:从抗癌和抗炎到神经保护。
Molecules. 2018 Feb 22;23(2):474. doi: 10.3390/molecules23020474.
7
EFAD transgenic mice as a human relevant preclinical model of Alzheimer's disease.EFAD转基因小鼠作为阿尔茨海默病的一种与人类相关的临床前模型。
J Lipid Res. 2017 Sep;58(9):1733-1755. doi: 10.1194/jlr.R076315. Epub 2017 Apr 7.
8
Poor dental hygiene and periodontal health in nursing home residents with dementia: an observational study.痴呆症养老院居民的口腔卫生状况差与牙周健康:一项观察性研究。
Odontology. 2017 Apr;105(2):208-213. doi: 10.1007/s10266-016-0246-5. Epub 2016 May 9.
9
Response to cholinesterase inhibitors affects lifespan in Alzheimer's disease.对胆碱酯酶抑制剂的反应影响阿尔茨海默病的寿命。
BMC Neurol. 2014 Sep 10;14:173. doi: 10.1186/s12883-014-0173-4.
10
Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophrenia.激活M1和M4毒蕈碱受体作为阿尔茨海默病和精神分裂症的潜在治疗方法。
Neuropsychiatr Dis Treat. 2014 Jan 28;10:183-91. doi: 10.2147/NDT.S55104. eCollection 2014.